[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335600-105":59,"doc-detail-335600-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","harnessing-antibody-mediated-recognition-of-the-intracellular-proteome-with-t-cell-receptorlike-specificity","Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptorlike specificity","","Cancer immunotherapy seeks novel targets that can drive potent effector functions to eliminate malignant cells. Traditional approaches have emphasized surface antigens, yet these cover only a small fraction of the cancer proteome. Most proteins are intracellular and are presented as short peptides by MHC class I molecules, enabling peptide-MHC complexes as an expansive, largely untapped resource. The review discusses how intracellular-derived peptide-MHC targets can be exploited using T-cell receptors or TCR-mimicking TCR-like antibodies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-antibody-mediated-recognition-of-the-intracellular-proteome-with-t-cell-receptorlike-specificity/335600/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-antibody-mediated-recognition-of-the-intracellular-proteome-with-t-cell-receptorlike-specificity/335600.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the review focus on intracellular proteins and peptide-MHC complexes?","Question",{"text":112,"@type":113},"Most proteins in the human proteome are intracellular, and intracellular peptides are presented on the cell surface by MHC class I molecules. This makes peptide-MHC complexes a large, underused source of potential cancer immunotherapy targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are TCR-like (TCRL) antibodies?",{"text":117,"@type":113},"TCRL antibodies are TCR-mimicking antibodies that can bind peptide-MHC complexes similarly to specific T-cell receptors. They are discussed as tools for targeting intracellular-derived antigens on malignant cell surfaces.",{"name":119,"@type":110,"acceptedAnswer":120},"What types of therapeutic approaches are highlighted for targeting the intracellular proteome?",{"text":121,"@type":113},"The review covers adoptive cell transfer of TCR-engineered or TCRL-T cells, CAR-T cells targeting peptide-MHC complexes, and soluble TCR- and TCRL-based agents such as bispecific T cell engagers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335600,1790176259,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","TYPE Review  \nPUBLISHED 22 November 2024 DOI 10.3389/fimmu.2024.1486721  \nOPEN ACCESS  \nEDITED BY  \nFabio Nicolini,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy  \nREVIEWED BY  \nChristian Augsberger, GSK, Germany Zhenyu Dai,  \nStanford University, United States  \n*CORRESPONDENCE  \nYoram Reiter  \n [reiter@technion.ac.il](reiter@technion.ac.il)  \nRECEIVED 26 August 2024  \nACCEPTED 05 November 2024  \nPUBLISHED 22 November 2024  \nCITATION  \nHaus-Cohen M and Reiter Y (2024)  \nHarnessing antibody-mediated recognition of the intracellular proteome with T cell receptorlike speciﬁcity.  \nFront. Immunol. 15:1486721 .  \ndoi: 10.3389/fimmu.2024.1486721  \nCOPYRIGHT  \n© 2024 Haus-Cohen and Reiter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHarnessing antibody-mediated recognition of the intracellular proteome with T cell receptorlike speciﬁcity  \nMaya Haus-Cohen and Yoram Reiter*  \nLaboratory of Molecular Immunology and Immunotherapy, Faculty of Biology Technion – Israel Institute of Technology, Haifa, Israel  \nThe clinical success of cancer immunotherapy has driven ongoing efforts to identify novel targets that can effectively guide potent effector functions to eliminate malignant cells. Traditionally, immunotherapies have focused on surface antigens; however, these represent only a small fraction of the cancer proteome, limiting their therapeutic potential. In contrast, the majority of proteins within the human proteome are intracellular, yet they are represented on the cell surface as short peptides presented by MHC class I molecules. These peptideMHC complexes offer a vast and largely untapped resource for cancer immunotherapy targets. The intracellular proteome, including neo-antigens, presents an exciting opportunity for the development of novel cell-based and soluble immunotherapies. Targeting these intracellular-derived peptide-MHC molecules on malignant cell surfaces can be achieved using speciﬁc T-cell receptors (TCRs) or TCR-mimicking antibodies, known as TCR-like (TCRL) antibodies. Current therapeutic strategies under investigation include adoptive cell transfer of TCR-engineered or TCRL-T cells and CAR-T cells that target peptide-MHC complexes, as well as soluble TCR-and TCRL-based agents like bispeciﬁc T cell engagers . Recent clinical developments in targeting the intracellular proteome using TCRL- and TCR-based molecules have shown promising results, with two therapies recently receiving FDA approval for the treatment of unresectable or metastatic uveal melanoma and synovial sarcoma. This review focuses on the processes for selecting and isolating TCR-and TCRLbased targeting moieties, with an emphasis on pre-clinical and clinical studies that explore the potential of peptide-MHC targeting agents in cancer immunotherapy.  \nKEYWORDS  \nimmunotherapy, CAR-T cells, TCR -T cell receptor, TCR-like antibodies (TCRL), bispeciﬁc antibodies  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nWhen it comes to therapeutic interventions, the cell surface and intracellular proteomes represent distinct but equally vital landscapes for drug discovery and development. Understanding the differences between these proteomes is essential for designing effective treatments, particularly in the context of diseases such as cancer, autoimmune disorders, and infectious diseases.  \nThe cell surface proteome, comprising proteins that reside on the outer membrane of cells, is the most accessible part of the cell’s molecular machinery. These proteins are directly exposed to the extrac","cbCaigjrsiQukwjv","https://ap.wps.com/l/cbCaigjrsiQukwjv","pdf",1471313,14,"English","# Introduction\n## Cell surface proteome and therapeutic targeting\n## Intracellular proteome challenges and opportunities\n## Antibody strategies targeting intracellular-derived peptides","[{\"question\":\"Why does the review focus on intracellular proteins and peptide-MHC complexes?\",\"answer\":\"Most proteins in the human proteome are intracellular, and intracellular peptides are presented on the cell surface by MHC class I molecules. This makes peptide-MHC complexes a large, underused source of potential cancer immunotherapy targets.\"},{\"question\":\"What are TCR-like (TCRL) antibodies?\",\"answer\":\"TCRL antibodies are TCR-mimicking antibodies that can bind peptide-MHC complexes similarly to specific T-cell receptors. They are discussed as tools for targeting intracellular-derived antigens on malignant cell surfaces.\"},{\"question\":\"What types of therapeutic approaches are highlighted for targeting the intracellular proteome?\",\"answer\":\"The review covers adoptive cell transfer of TCR-engineered or TCRL-T cells, CAR-T cells targeting peptide-MHC complexes, and soluble TCR- and TCRL-based agents such as bispecific T cell engagers.\"}]","Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptorlike specificity | PDF",1790011582,35]